Skip to main content

Balyasny Asset Management L.P.

Position in SMMT — Summit Therapeutics Inc.

CIK 1218710 Chicago, IL

Position in SMMT

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$27,744,980
+$17,348,550 QoQ
Shares Held
1,904,254
+247.3% QoQ
Ownership
0.239%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#14
of 242 holders
Holding Since
Mar 2023
11 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in SMMT Over Time

Shares Held

Position Value (USD)

Derivatives in SMMT

reported options exposure · as of Jun 30, 2025
CallValue
$808,640
CallShares
38,000
PutValue
$268,128
PutShares
12,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Balyasny Asset Management L.P. holds $2,351,657,469 across 178 Biotechnology names. SMMT ranks #23 (1.2% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in SMMT

Export CSV
13 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $27,744,980 1,904,254
2026-03-31 $10,396,430 548,335
2025-12-31 $879,712 50,298
2025-09-30 $4,025,621 194,851
2025-06-30 $268,128 12,600
2025-06-30 $808,640 38,000
2025-03-31 $32,854,342 1,703,180
2025-03-31 $6,213,309 322,100
2024-12-31 $6,910,333 387,242
2024-09-30 $9,442,754 431,176
2024-06-30 $7,879,224 1,010,157
2023-06-30 $25,494 10,157
2023-03-31 $62,235 35,563